-
All Resources
(choose a category)
-
All Resources
-
Evidence
Evidence, advice, guidance and standards
-
Improvement
Improvement and implementation support
-
Scrutiny
Assurance, scrutiny, measurement and reporting
-
-
Healthcare Area
- Blood and immune system
- Cancer
- Cardiovascular system
- Caring for older people
- Dermatology
- Digestive system
- Ear, nose and throat
- Endocrine, nutritional and metabolic
- Eye
- Genitourinary system
- Health service organisation and delivery
- Infectious disease
- Injuries, accidents and wounds
- Learning disability
- Mental and behavioural disorders
- Mouth and dental
- Musculoskeletal system
- Nervous system
- Obstetrics and gynaecology
- Paediatrics
- Palliative care
- Patient experience
- Physical disability
- Public health
- Respiratory system
- Resource Type
-
Programme
- Cancer care improvement
- Cardiovascular disease
- Clinical engagement
- Early Years, Maternal and Reproductive Health
- Governance and assurance
- Inspection and regulation of healthcare services
- Long term conditions
- Mental health
- OPAH Tayside
- Patient experience
- Patient safety
- Primary care
- Programmes
- Technologies and medicines
- Year
-
Healthcare Improvement Scotland Equality Mainstreaming Report
- Published
- 29 April 2013
- Cycle of Improvement
- None
-
Healthcare Improvement Scotland Equality Outcomes 2013-2017
- Published
- 29 April 2013
- Cycle of Improvement
- None
-
Healthcare Improvement Scotland Equal Pay Review
- Published
- 29 April 2013
- Cycle of Improvement
- None
-
Equality Act 2010 (Specific Duties) (Scotland) Regulations 2012 - Equal Pay Statement
- Published
- 29 April 2013
- Cycle of Improvement
- None
-
Western General unannounced HAI inspection Apr 2013
- Published
- 24 April 2013
- Cycle of Improvement
- Scrutiny
-
NICE MTA guidance no 278 - Omalizumab for treating severe persistent allergic asthma
- Published
- 24 April 2013
- Cycle of Improvement
- Evidence
-
NICE STA guidance no 280 - Rheumatoid arthritis (2nd line) - abatacept (rapid review of TA 234)
- Published
- 24 April 2013
- Cycle of Improvement
- Evidence
-
NICE STA guidance no 281 - Canakinumab for gout – terminated appraisal
- Published
- 24 April 2013
- Cycle of Improvement
- Evidence
-
NICE STA Guidance no 282 - Idiopathic pulmonary fibrosis - pirfenidone
- Published
- 24 April 2013
- Cycle of Improvement
- Evidence
-
NICE MTA Guidance no 279 - Percutaneous vertebroplasty and percutaneous balloon kyphoplasty
- Published
- 24 April 2013
- Cycle of Improvement
- Evidence